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The ileal apical sodium bile acid cotransporter partic-
ipates in the enterohepatic circulation of bile acids. In
patients with primary bile acid malabsorption, muta-
tions in the ileal bile acid transporter gene (Slc10a2)
lead to congenital diarrhea, steatorrhea, and reduced
plasma cholesterol levels. To elucidate the quantitative
role of Slc10a2 in intestinal bile acid absorption, the
Slc10a2 gene was disrupted by homologous recombina-
tion in mice. Animals heterozygous (Slc10a2/) and ho-
mozygous (Slc10a2/) for this mutation were physically
indistinguishable from wild type mice. In the Slc10a2/
mice, fecal bile acid excretion was elevated 10- to 20-fold
and was not further increased by feeding a bile acid
binding resin. Despite increased bile acid synthesis, the
bile acid pool size was decreased by 80% and selectively
enriched in cholic acid in the Slc10a2/ mice. On a low
fat diet, the Slc10a2/ mice did not have steatorrhea.
Fecal neutral sterol excretion was increased only 3-fold,
and intestinal cholesterol absorption was reduced only
20%, indicating that the smaller cholic acid-enriched
bile acid pool was sufficient to facilitate intestinal lipid
absorption. Liver cholesteryl ester content was reduced
by 50% in Slc10a2/ mice, and unexpectedly plasma
high density lipoprotein cholesterol levels were slightly
elevated. These data indicate that Slc10a2 is essential
for efficient intestinal absorption of bile acids and that
alternative absorptive mechanisms are unable to com-
pensate for loss of Slc10a2 function.
Bile acids are synthesized from cholesterol in the liver and
secreted into the small intestine where they facilitate the ab-
sorption of dietary lipids and fat-soluble vitamins. The majority
of bile acids are reabsorbed from the intestine, returned to the
liver via the portal venous circulation, and resecreted into bile
(1). The enterohepatic circulation of bile acids is an extremely
efficient process; less than 10% of intestinal bile acids escape
reabsorption and are eliminated in the feces. In the intestine,
bile acids are reclaimed through a combination of passive ab-
sorption in the jejunum, active transport in the distal ileum,
and passive absorption in the colon (2). Bile acids are actively
transported in the terminal ileum by the well characterized
ileal apical sodium bile acid cotransporter (ASBT1; gene name
Slc10a2) (3, 4). This sodium- and potential-driven transporter
moves bile acids from the lumen of the small intestine across
the apical brush border membrane. Bile acids are then shuttled
to the basolateral membrane and secreted into the portal
circulation.
Several observations support the concept that the terminal
ileum is the major site of bile acid reabsorption, including the
finding that there is little decrease in intraluminal bile acid
concentration prior to the ileum (5) and the appearance of bile
acid malabsorption after ileal resection (6). More recent studies
using in situ perfused intestinal segments to measure bile acid
absorption (7–9) have also demonstrated that ileal active bile
acid transport is a high capacity system sufficient to account
for the biliary output of bile acids. Finally, patients with a rare
inherited Slc10a2 defect exhibit bile acid malabsorption, re-
fractory infantile diarrhea, steatorrhea, and failure to thrive
(primary bile acid malabsorption), underscoring the impor-
tance of Slc10a2 in the human infant (10, 11). The consensus
from these studies was that the ileal active transport system is
a major route for bile acid uptake, but passive absorption
present down the length of the intestine may also be signifi-
cant. Thus, the overall quantitative contribution of passive
jejunal and/or colonic bile acid absorption is not known. To
resolve this question and to further understand the role of
Slc10a2 in bile acid and cholesterol homeostasis, we have pro-
duced a line of mice with a targeted disruption in the Slc10a2
gene.
EXPERIMENTAL PROCEDURES
Generation of Slc10a2/ Mice—The targeting vector was con-
structed as shown (see Fig. 1A). The Slc10a2 region extending from
intron 2 through the splice acceptor site of exon 4 was replaced with a
neomycin-containing cassette in the pPNT vector (12). The targeting
vector was linearized by cleavage with NotI and introduced by electro-
poration into mouse embryonic stem cells as described (13). Appropriate
targeting of the Slc10a2 allele was confirmed by Southern blotting (see
Fig. 6A in Supplemental Material). Male chimeric progeny were crossed
with female C57BL/6J (Jackson Laboratory) and 129S6/SvEv (Taconic)
mice to generate two independent lines of mice carrying the disrupted
Slc10a2 allele. Unless indicated, the congenic 129S6/SvEv line was
used for the experiments in this study.
Animals and Diet—All animal procedures were approved by the
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Institutional Animal Care and Use Committee. Mice were maintained
on a prepared basal diet (14) supplemented with vitamins, cholesterol,
or a bile acid binding resin as required. The basal diet contains 16% fat,
20% protein, 64% carbohydrate (% of calories), and 0.017 mg/calorie of
cholesterol (0.006%) (w/w). The diets for all pregnant and nursing dams
were initially supplemented with vitamins (ADEKs pediatric drops;
ScandiPharm, Inc., Birmingham, AL); however, this supplementation
was later shown to be unnecessary for survival of the Slc10a2 null
progeny. The compositions of the experimental diets used in these
studies are shown in Table III of the Supplemental Material.
RNA Analyses—Total RNA was extracted from frozen tissue using
TRIzol reagent (Invitrogen) as suggested by the manufacturer. For
Northern blot analysis, total RNA from individual animals or pools of
animals of the same sex and genotype was fractionated on 1.2% (w/v)
agarose gels containing 2.2 M formaldehyde, transferred to Nytran (0.45
m; Schleicher & Schuell), and hybridized with the indicated 32P-
labeled random hexamer-primed DNA probes. Expression levels were
quantified using a PhosphorImager (Amersham Biosciences).
Preparation of Intestinal BBMV and Measurement of Ileal Bile Acid
Transporter Protein and Activity—Small intestines from wild type and
Slc10a2 null mice (mixed C57BL/6:129S6/SvEv background) were di-
vided into five sections of equal length and used to isolate brush border
membranes by the calcium precipitation method (15). Membrane vesi-
cle transport was assayed in triplicate using freshly isolated ileal
BBMV from mice of the indicated genotype (16). Immunoblotting anal-
ysis of ileal bile acid transporter protein was performed as described
(17) using a rabbit anti-ileal bile acid transporter antibody. The blots
were also probed using mouse anti--actin antibody as a control for
protein loading.
Fecal Bile Acid and Lipid Excretion—Wild type and Slc10a2 null
mice in the congenic 129S6/SvEv background were individually housed
in wire bottom cages, and stools were collected for 3 days. The stools
were extracted as described by Turley et al. (18) and used to determine
the total bile acid content by an enzymatic method (19). For a subset of
animals, the fecal bile acid species were also analyzed by mass spec-
trometry using an Agilent Technologies HP1100 atmospheric pressure
ionization-electrospray instrument (20). A second 0.1-g aliquot of dried
stool was used to measure neutral sterol and fatty acid content by
gas-liquid chromatography (14, 21). Intestinal cholesterol absorption
was measured using a modification of the fecal dual isotope ratio
method (22).
Bile Acid Pool Size and Composition—Pool size was determined as
the bile acid content of the small intestine, liver, and gallbladder. These
tissues were removed and extracted in ethanol as described (23). The
extract was filtered, and bile acid composition was determined using
HPLC as described by Rossi et al. (24). Individual bile acid species were
detected by measuring refractive index; the total bile acid content of the
tissue extracts was measured using an enzymatic assay (19). For a
subset of animals, the bile acid species were also analyzed by electro-
spray mass spectrometry. The lumenal contents of the proximal small
intestine were also collected to measure the molar ratio of bile acids to
cholesterol in the liquid phase of intestinal contents as described by
Repa et al. (25).
Cholesterol 7-Hydroxylase—CYP7A1 protein was detected using a
chicken polyclonal antibody raised against a maltose-binding protein
(New England BioLabs) fusion encompassing amino acids 353 to 436 of
the African green monkey CYP7A1 (26). The blots were also probed
using a rabbit anti-BIP antibody (27) as a control for protein loading.
CYP7A1 protein expression was quantified by scanning the x-ray films
using an Alpha Innotec (San Leandro, CA) 5500 imaging system.
CYP7A1 enzyme activity was measured in microsomes isolated from
individual animals using a reverse phase HPLC assay (28).
Plasma and Hepatic Lipids—Plasma total cholesterol (Wako), free
cholesterol (Wako), and triglyceride (Roche Applied Science) concentra-
tions were determined by enzymatic assay (29). An aliquot of pooled
plasma from five animals in each group was fractionated on a 30  1-cm
Superose 6 column, and the cholesterol content of each lipoprotein
fraction was detected using an on-line enzymatic assay. Hepatic tri-
glyceride content was determined by enzymatic assay (29). Hepatic free
and total cholesterol was determined by gas-liquid chromatography
(14).
Statistical Analyses—Mean values  S.E. are shown. The data were
evaluated for statistically significant differences using the two-tailed
Student’s t test assuming equal variance. The data from the diet studies
were evaluated using analysis of variance with post hoc analysis for
individual group differences by the Fisher’s protected least significant
difference test (Statview; Mountain View, CA). Differences were con-
sidered statistically significant at p  0.05.
RESULTS
Inactivation of the Slc10a2 Gene in Mice—The region extend-
ing from intron 2 through the splice acceptor site of exon 4 was
replaced with a neomycin-containing cassette by homologous
recombination (Fig. 1A). Gene disruption was confirmed by
Southern blotting (see Fig. 6A in Supplemental Material),
Northern blotting (Fig. 1B), and immunoblotting (Fig. 1B). No
ASBT mRNA or immunoreactive protein was detected in the
distal small intestine of Slc10a2 null mice. ASBT is thought to
be the only sodium bile acid cotransporter expressed in the ileal
apical brush border membrane (30). To directly test this hy-
pothesis, apical BBMV were isolated and used to measure
sodium-dependent taurocholate uptake. In ileal BBMV from
wild type mice, [3H]taurocholate (25 M) uptake was increased
42-fold in the presence of an inwardly directed Na gradient
compared (p  0.0001). In contrast, there was no Na-depend-
ent taurocholate uptake in ileal BBMV isolated from Slc10a2
null mice (Fig. 1C). The integrity of the BBMV preparations
was confirmed by measuring Na-alanine cotransport. Na-
coupled [3H]alanine uptake (125 M) was similar in BBMV
isolated from both mouse genotypes (Slc10a2/, 175  35
pmol/mg protein/15 s versus Slc10a2/, 218  60 pmol/mg
protein/15 s; p  0.5).
Analysis of the Slc10a2/ Mice—The Slc10a2/ mice are
viable and fertile. Crossing heterozygous mice produced a Men-
delian distribution of wild type and mutant genotypes. The
Slc10a2/ mice were indistinguishable in terms of survival,
gross appearance, and behaviors from Slc10a2/ and wild
type animals. A small growth deficit was observed in male but
not female Slc10a2 null mice compared with wild type litter-
mates prior to weaning at day 21 (data not shown). However,
the 20% decrease in body weight of male Slc10a2/ pups
was only transitory, and adult body weights and daily fecal
excretion (dry weight) were similar between the different gen-
otypes (see Fig. 7, A and B in Supplemental Material). This
phenotype is very different from that originally reported for the
Cyp7a1 null mice (31, 32). The Cyp7a1/ mice fail to thrive
and experience a very high rate of postnatal mortality unless
supplemented with exogenous fat-soluble vitamins and cholic
acid. In contrast, survival of Slc10a2/ mice was indistin-
guishable from wild type littermates regardless of vitamin
supplementation for the pregnant and nursing dams.
Possible explanations for the normal postnatal phenotype of
the Slc10a2/ mice include alternative intestinal uptake
mechanisms that compensate for the loss of Slc10a2 function,
increased bile acid synthesis that is able to compensate for the
intestinal bile acid loss, or other metabolic adaptations that are
able to maintain fat absorption and lipid homeostasis. To dis-
tinguish among these possibilities, bile acid and lipid metabo-
lism was examined in the wild type and Slc10a2/ mice. As
shown in Fig. 2A, fecal bile acid excretion was elevated 24- and
11-fold in male and female Slc10a2/ mice, respectively.
Analysis of the fecal bile acid composition by electrospray mass
spectrometry revealed that both genotypes excrete similar bile
acid species; however, the total amount of bile acids excreted
was greater in the Slc10a2 null mice. These results indicate
that alternative intestinal uptake mechanisms are not compen-
sating for the active ileal absorption.
Increased bile acid synthesis is a well recognized mechanism
to compensate for disruption of the enterohepatic circulation of
bile acids (33–35). To determine whether synthesis is able to
compensate in the Slc10a2 null mice, the bile acid pool size and
composition were measured. As shown in Fig. 2B, the total bile
acid pool was decreased 83 and 80% in the Slc10a2/ males
and females, respectively. A crude fractional turnover rate
(FTR) can be calculated, because the daily rate of fecal bile acid
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excretion and bile acid pool size were measured in these same
animals. The bile acid FTR (daily fecal bile acid excretion/pool
size) was 0.13 pools/day in wild type mice (males, 0.13  0.03
pools/day; females, 0.12  0.02 pools/day). The bile acid FTR
was remarkably elevated in the Slc10a2 null mice, increasing
150-fold in the males (19.22  2.33 pools/day) and 75-fold in
the females (9.26  2.49 pools/day).
Composition of the bile acid pool was significantly altered in
the Slc10a2/ mice. The primary bile acids taurocholate and
tauro--muricholate account for 90% of the pool in the male
(taurocholate 43%, tauro--muricholate 49%) and female (tau-
rocholate 53%, tauro--muricholate 34%) wild type mice. How-
ever, in the Slc10a2 null mice, the fraction of the pool normally
occupied by tauro--muricholate is largely replaced by tauro-
cholate, such that taurocholate became the major bile acid
species accounting for 81% (males) and 70% (females) of the
bile acid pool. The proportion of tauro--muricholate was sig-
nificantly decreased to 10% of the pool in the Slc10a2 null
mice. The remainder of the bile acid pool in the wild type and
Slc10a2 null mice consisted primarily of taurodeoxycholate,
tauro--muricholate, and tauro--muricholate. No unconju-
gated bile acids were detected in the bile acid pool by electro-
spray mass spectrometry (data not shown).
Intestinal Cholesterol and Total Lipid Absorption—Varia-
tions in bile acid pool size and composition affect lipid absorp-
tion from the small intestine. In general, large decreases in the
pool size and/or content of hydrophobic bile acids can decrease
lipid absorption (36, 37). The diminished bile acid pool in the
Slc10a2 null mice raises the possibility that cholesterol and
total lipid absorption are impaired. Analysis of the fecal lipid
excretion revealed that male and female Slc10a2/ mice ex-
crete 4-fold more total fat, fatty acids, and neutral sterols
than wild type mice (Fig. 2C). However, the total amount of fat
excreted is still small. The stool fat content as a percentage of
fecal dry weight was 1.5 and 4.2% in wild type and Slc10a2
null mice, respectively. Intestinal lipid absorption was esti-
mated by measuring the daily food consumption and lipid con-
tent of the diet. The percent of intestinal lipid absorption de-
creased from 98 to 93% in males and from 98 to 95% in
female Slc10a2 null mice. These studies indicate that despite
an 80% decrease in the bile acid pool, total intestinal lipid
absorption was decreased less than 10%. Cholesterol absorp-
tion has been reported to be more sensitive than total lipid to
changes in bile acid pool size or composition (23, 36). To further
investigate this question in the Slc10a2 null mice, intestinal
cholesterol absorption was measured using the fecal dual iso-
tope ratio method. As shown in Fig. 2D, intestinal cholesterol
absorption was decreased 26% (males) and 15% (females) in the
Slc10a2/ mice maintained on the low cholesterol-containing
basal diet. These results suggest that despite the 80% decrease
in bile acid pool size, there are sufficient lumenal bile acids for
micellar solubilization of cholesterol. This was confirmed by
direct measure of the bile acid to cholesterol ratio in the liquid
phase of the proximal small intestine lumenal contents. The
molar ratio of bile acids to cholesterol was 296  28 (n  4) in
the wild type mice versus 107  15 (n  5) in the Slc10a2 null
mice (p  0.0004).
Cyp7a1 Expression—In the mouse, the majority of bile acids
are synthesized via the CYP7A1 pathway (23). CYP7A1 activ-
ity was significantly increased in both male (2.7-fold) and fe-
male (5.2-fold) Slc10a2/ mice (Fig. 3A). Similar increases
were seen for CYP7A1 protein and mRNA levels (Fig. 3B). In
addition to the pooled samples shown in Fig. 3B, aliquots of
microsomes and mRNA from individual mouse livers were an-
alyzed for CYP7A1 expression. CYP7A1 protein was increased
4.1-fold in male (p  0.0013) and 6.9-fold in female (p  0.0001)
FIG. 1. Targeted disruption of the ileal apical sodium-depend-
ent bile acid transporter gene (Slc10a2). A, schematic representa-
tion of the wild type Slc10a2 gene (Wild type allele) showing the loca-
tions of exons 1 to 6 and the restriction enzyme cleavage sites used to
construct the targeting vector that contains one copy of the herpes
simplex virus thymidine kinase (hsv-TK) gene and a neomycin resist-
ance gene (neo). All of exon 3 and the splice acceptor site of exon 4 are
replaced by the neomycin resistance gene as a result of homologous
recombination (Targeted allele) between the targeting vector and the
wild type allele. B, BamHI; E, EcoRI; H, HaeIII. B, Slc10a2 mRNA and
protein expression in small intestinal segments of mice with the indicated
genotypes. The small intestine was divided into five segments of equal
length and used to isolate RNA and brush border membranes. Aliquots (5
g) of total RNA were subjected to Northern blot hybridization using
radiolabeled probes derived from the coding regions of Slc10a2 and actin.
Aliquots of intestinal brush border membrane protein (100 g) were
subjected to immunoblotting analysis using antibodies to the Slc10a2 and
-actin. C, solute transport in ileal brush border membranes from wild
type and Slc10a2 null mice. Ileal brush border membrane vesicles were
incubated for 15 s with 25 M [3H]taurocholate in the presence of 137 mM
NaCl (open bar) or KCl (closed bar). Each bar represents mean  S.E. (n 
6). Sodium-taurocholate cotransport was absent in the ileal brush border
membranes isolated from Slc10a2/ mice (*p  0.0001).
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Slc10a2 null mice. Similarly, CYP7A1 mRNA was increased
3-fold (p  0.0013) and 2.3-fold (p  0.02) in the male and
female Slc10a2 null mice, respectively.
Intestinal Bile Acid Absorption—In addition to Slc10a2-me-
diated transport in the terminal ileum, bile acids may be ab-
sorbed by passive non-ionic diffusion in the small intestine, by
facilitative transport in the small intestine, or by passive dif-
fusion in the colon following bacterial metabolism. The first
mechanism is unlikely to be an important contributor, because
mouse bile acids are conjugated to taurine and would be ionized
at physiological pH of the small intestine. The quantitative
significance of the second mechanism, facilitative transport of
conjugated bile acids, is unknown (38–41). A candidate trans-
porter for this activity, Oatp3, has been identified in proximal
small intestine (42). However, Oatp3 is expressed at negligible
levels in rodent small intestine (42), and its mRNA expression
is not induced in the Slc10a2 null mice (data not shown). It is
therefore unlikely that Oatp3 accounts for appreciable intesti-
nal bile acid absorption. A third mechanism involves conver-
sion of taurocholate to deoxycholate following deconjugation
and 7-dehydroxylation by the endogenous bacterial flora (43).
Deoxycholate produced in the colon undergoes passive non-
ionic diffusion, and it has been proposed that colonic absorption
becomes the major route of intestinal absorption when ileal
function is impaired (44). To determine the contribution of
these alternative mechanisms for intestinal bile acid absorp-
tion, Slc10a2 null mice were fed a semipurified diet containing
2% colestipol, a bile acid binding resin. Bile acid sequestrants
should have little effect on fecal bile acid excretion if Slc10a2 is
the single major mechanism for intestinal bile acid transport.
Conversely if alternative mechanisms such as colonic absorp-
tion are important in the mouse, colestipol should increase
fecal bile acid excretion. As a control, a separate group of mice
were fed a semipurified diet containing 1% cholesterol to de-
termine whether substrate has become rate-limiting for bile
acid synthesis in the Slc10a2 null mice. As shown in Fig. 4A,
fecal bile acid excretion increased significantly in the wild type
mice following cholesterol feeding (3-fold versus basal diet; p 
0.0152) or colestid feeding (9-fold versus basal diet; p  0.0001).
In contrast, cholesterol feeding (p  0.2268) and colestipol
feeding (p  0.4860) had little effect on the already elevated
fecal bile acid excretion rate in the Slc10a2 null mice. CYP7A1
mRNA expression (Fig. 4B) followed a similar pattern. These
data indicate that the non-Slc10a2 mechanisms contribute lit-
tle to intestinal bile acid absorption in the mouse.
Hepatic and Plasma Lipids—The changes in hepatic lipid
and lipoprotein concentrations are described in Table I. He-
patic and plasma triglyceride levels were similar in wild type
and Slc10a2 null mice. In contrast, hepatic cholesteryl ester
levels were significantly lower in the basal diet-fed Slc10a2/
mice reflecting the increased bile acid synthesis in these ani-
mals (Table I). Surprisingly, the male and female Slc10a2/
mice had a small but significant (p  0.001) increase in their
total plasma cholesterol levels. Analysis of the plasma by fast
FIG. 2. Fecal lipid excretion and bile acid pool size in wild type and Slc10a2 null mice. Mean values  S.E. are shown. A, fecal bile acid
excretion was measured as described under “Experimental Procedures” (n  10). Bile acid excretion in Slc10a2/ mice was significantly greater
(*, p  0.0001 for males and p  0.0002 for females) than for the wild type mice. B, the mass of bile acid in the enterohepatic circulation was
determined by extraction, purification, and quantitation using HPLC (n  6–10). The Slc10a2/ mice had a significantly decreased total bile acid
pool size (*p  0.0001), as well as decreased amounts of taurocholate (p  0.0001) and tauro--muricholate (p  0.001 for males and p  0.0002
for females). The small amount of other bile acids in the pool were not significantly different between the two genotypes (p  0.05). C, fecal neutral
sterols and fatty acids were quantitated by gas chromatography (n  10). The Slc10a2/ mice had significantly increased total fat excretion
(*, p  0.0001 for males and p  0.0001 for females), fatty acid excretion (p  0.0001 for males and p  0.0001 for females), and neutral sterol
excretion (p  0.0001). D, intestinal cholesterol absorption was measured by a dual isotope fecal assay (n  10). The Slc10a2/ mice had
significantly decreased intestinal cholesterol absorption (*, p  0.026 for males and p  0.0009 for females).
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protein liquid chromatography revealed no lipoprotein particle
size differences between the null and wild type mice (data not
shown), and almost all the cholesterol was found in the high
density lipoprotein (HDL) fraction (Table I).
Alterations in Gene Expression—To identify possible com-
pensatory mechanisms engaged in response to bile acid malab-
sorption, we quantified mRNA levels for candidate genes in-
volved in cholesterol and bile acid metabolism (Fig. 5). An
increased level of sterol 12-hydroxylase (Cyp8b1) was de-
tected in the Slc10a2/ mice, consistent with the increased
proportion of cholate in the bile acid pool (Fig. 2B). An in-
creased level of sterol 27-hydroxylase mRNA was also detected.
Expression of the hepatic bile salt export pump (Abcb11) was
reduced in the Slc10a2/ mice, presumably in response to the
decreased hepatic flux of bile acids in the enterohepatic circu-
lation. The greatest mRNA increases were observed for en-
zymes in the cholesterol biosynthetic pathway. The mRNA for
HMG CoA synthase was elevated 5- to 7-fold, where HMG CoA
reductase was increased 3- to 6-fold. Relatively small changes
were observed for several of the nuclear receptors important for
cholesterol and bile acid homeostasis, including LXR, FXR,
and LRH. In contrast, SHP expression was unchanged in the
males and dramatically reduced in the female Slc10a2 null
mice.
DISCUSSION
The major finding of this study is that disruption of Slc10a2
resulted in profound bile acid malabsorption, and jejunal/co-
lonic absorption contributed little to intestinal conservation of
bile acids in the mouse. Intestinal uptake of bile acids was
thought to be the result of a combination of passive absorption
in the jejunum, active transport in the distal ileum, and passive
absorption in the colon (2). Uptake is transcellular, and there is
little evidence of paracellular absorption of bile acids in any of
these compartments (45, 46). Slc10a2 is responsible for active
ileal bile acid uptake (30), and most studies support the concept
that the terminal ileum is an important site of bile acid absorp-
tion, including the finding that inherited mutations in human
Slc10a2 causes bile acid malabsorption (10). However, the non-
Slc10a2 contribution to intestinal bile acid absorption was not
quantified in primary bile acid malabsorption subjects, and
there is a persistent body of evidence for significant jejunal
absorption (38–41). In addition, the endogenous bacterial flora
FIG. 3. Bile acid synthesis and expression of CYP7A1. Mean
values  S.E. are shown (n  4–5). A, CYP7A1 enzyme activity was
measured using an HPLC-based assay and hepatic microsomes isolated
from mice of the indicated sex and Slc10a2 genotype. CYP7A1 activity
was significantly greater in the Slc10a2/ mice (*, p  0.0136 for
males and p  0.0001 for females) than for the wild type mice. B,
CYP7A1 protein and mRNA levels in liver of wild type and Slc10a2/
mice. Microsomes were pooled from four to five animals, and 100 g of
microsomal protein was subjected to immunoblotting as described un-
der “Experimental Procedures.” The blots were probed using anti-BIP
antibody as a control. CYP7A1 protein was elevated 5-fold in the
Slc10a2/ mice. Pooled aliquots of total RNA were subjected to North-
ern blot hybridization using radiolabeled probes for CYP7A1 and cyclo-
philin. CYP7A1 mRNA was elevated 4-fold in the Slc10a2 null mice.
FIG. 4. Changes in bile acid excre-
tion and cholesterol 7-hydroxylase
mRNA expression in response to die-
tary cholesterol and colestipol. A,
male mice of different Slc10a2 genotypes
were fed the indicated diets for 21 days.
Mean values  S.E. (n  4–5) are shown.
Fecal bile acid excretion was measured as
described under “Experimental Proce-
dures.” Fecal bile acid excretion was sig-
nificantly increased in the wild type mice
by cholesterol (*, p  0.0152) and cho-
lestyramine (*, p  0.0001) feeding. In
contrast, cholesterol or colestid feeding
did not significantly change bile acid ex-
cretion in the Slc10a2/ mice (p  0.2).
B, CYP7A1 mRNA levels in liver of wild
type and Slc10a2/ mice fed the indi-
cated diets. CYP7A1 and cyclophilin
mRNA levels were measured in pooled
aliquots (n  4–5) of liver total RNA by
Northern blot hybridization. The level of
CYP7A1 mRNA expression relative to the
wild type male mice is indicated.
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in the distal small intestine, cecum, and colon converts tauro-
cholate to deoxycholate, a more hydrophobic dihydroxy bile
acid that can undergo significant passive absorption (43). Al-
though only a minor contributor under normal physiologic con-
ditions, it had been proposed that colonic absorption of uncon-
jugated bile acids becomes a major route of intestinal
absorption when ileal function is impaired and bile acid flux
into the colon is high (44, 46). Generation of the Slc10a2 null
mouse made it possible to directly quantify the in vivo contribu-
tion of the jejunal and colonic absorptive pathways. Surprisingly,
physically sequestering bile acids using binding resins, a treat-
ment that interferes with intestinal bile acid absorption, had no
effect on fecal bile acid excretion in the Slc10a2 null mice.
There are several issues that must be considered before
extrapolating these findings to wild type mice or to humans.
First, mouse bile acids are conjugated with taurine and do not
undergo appreciable non-ionic passive diffusion across the
small intestinal epithelia. The bile acid glycine conjugates pres-
ent in man and many other species may undergo more passive
diffusion. Second, jejunal bile acid absorption in vivo may be a
low affinity process and could have been masked by the low
intralumenal bile acid concentrations in the Slc10a2 null
mouse. Third, colonic absorption of bile acids is dependent on
composition of the intestinal flora, pH of the lumenal contents,
and the intestinal transit time (47). Because only a very small
fraction of the intestinal flora harbors the bacterial genes nec-
essary to 7-dehydroxylate bile acids (43), differences in the
content of those specific anaerobic bacteria between species or
even between different mouse strains could alter deoxycholate
production. Finally, bile acids are bacteriostatic (48, 49), and
their increased flux into the cecum and colon in the Slc10a2
null mice may have reduced the bacterial content and deoxy-
cholate production in the distal small intestine and colon.
Variations in bile acid pool size and composition are known
to affect the amount of cholesterol absorbed from the small
intestine. A comparison of intestinal cholesterol absorption in
the Cyp7a1/, Cyp8b1/, and Slc10a2/ mice nicely illus-
trates these relationships. Slc10a2/ and Cyp7a1/ mice
have a similar 80% decrease in their bile acid pool (22, 35).
However, intestinal cholesterol absorption is dramatically re-
duced in the male Cyp7a1/ mice (decreased greater than
95%) but only mildly affected in the male Slc10a2/ mice
(decreased 26%). Conversely, Cyp8b1/ and Slc10a2/
mice show similar decreases in intestinal cholesterol absorp-
tion (40% in Cyp8b1/ and 25% in Slc10a2/) (36), but
the bile acid pool is increased in Cyp8b1/ mice (37%) and
dramatically reduced in the Slc10a2/ mice (80%). The
differences between these genotypes can be attributed to the
increased relative content of cholate in the Slc10a2/ mice.
Expression of the hepatic enzyme responsible for cholate syn-
thesis, Cyp8b1, is induced in response to decreased return of
bile acids in the enterohepatic circulation. This important ad-
TABLE I
Hepatic and plasma lipid levels
Male Slc10a2/ Male Slc10a2/ Female Slc10a2/ Female Slc10a2/
Hepatic lipids (mean  SE; n  10)
Free cholesterol (mg/g) 2.44  0.03 2.42  0.04 2.73  0.08 2.38  0.05a
Cholesteryl esters (mg/g) 4.58  0.68 2.66  0.39b 13.08  2.26 3.52  0.41b
Triglyceride (mg/g) 11.80  2.04 11.24  1.31 16.73  1.48 16.91  1.43
Plasma lipids (mean  S.E.; n  10)
Total cholesterol (mg/dl) 112  4 134  5a 109  7 127  5c
Triglyceride (mg/dl) 81  8 71  10 40  5 33  9
VLDL cholesterol (mg/dl) 7 2 3 1
LDL cholesterol (mg/dl) 12 12 16 12
HDL cholesterol (mg/dl) 94 120 96 115
a p  0.01 versus wild type.
b p  0.001 versus wild type.
c p  0.05 versus wild type.
FIG. 5. Gene expression in wild type and Slc10a2 null mice. Pooled aliquots of total RNA (5 g or 25 g) isolated from the liver (n  4–5)
were analyzed by Northern blot hybridization using cDNA probes for the indicated genes. The asterisk (*) indicates that 25 g of total RNA was
analyzed. Each blot was also hybridized with a cyclophilin cDNA probe to normalize relative expression levels. For each gene, the mRNA expression
level is indicated relative to the level found in wild type male mice.
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aptation enriches the smaller pool in Slc10a2 null mice with a
more hydrophobic bile acid, thereby supporting near normal
levels of intestinal cholesterol absorption. In contrast the bile
acid pool in the Cyp7a1/ and Cyp8b1/ mice are enriched
in more hydrophilic bile acids such as -muricholate that may
antagonize the ability of hydrophobic bile acids to solubilize
and deliver cholesterol to the intestinal epithelial cell (37).
Taken together, these data support the concept that bile acid
composition is more important than pool size for affecting sol-
ubilization and absorption of cholesterol from the intestinal
lumen. It is important to note that the mice in this study are
maintained on a diet low in fat (16% of calories) and cholesterol
(0.006%). The intestinal lipid absorption-sparing effect of
cholate enrichment in the Slc10a2 null mice may be lost when
challenged with diets containing more fat, such as a typical
Western diet.
In the Slc10a2 null mice, CYP7A1 expression and hepatic
bile acid synthesis was increased in response to the interrup-
tion of the enterohepatic circulation of bile acids. This in-
creased demand on hepatic cholesterol stores was only partially
offset by increased hepatic sterol synthesis. Hepatic total cho-
lesterol and cholesteryl ester levels were significantly reduced
in the male (40% decrease in cholesteryl ester) and female (75%
decrease in cholesteryl ester) Slc10a2 null mice. Despite this
decrease in hepatic total cholesterol, the Slc10a2 null mice had
a small but significant increase in total plasma cholesterol
levels. This increase was selective for the HDL fraction, and no
change was observed for plasma VLDL or LDL concentrations.
An increase in HDL cholesterol has been reported in the
Fxr/ mice and was attributed to impaired hepatic selective
removal of HDL cholesterol ester by SRBI (50). It is not clear if
a similar mechanism is responsible in the Slc10a2 null mice. In
contrast to the FXR null mice, SRBI mRNA expression was
unchanged in the Slc10a2/ mice. Another possible explana-
tion for the increase in HDL is that apoA-I expression is dere-
pressed in the Slc10a2/ mice. Several studies have found
that bile acids decrease apoA-I expression (51, 52), though this
bile acid repression has not been a universal finding (50).
Several lines of evidence indicate that changes in bile acid
metabolism affect plasma triglyceride levels. In humans, in-
creased plasma triglyceride levels are associated with interrup-
tion of the enterohepatic circulation using bile acid binding
resins or after ileal exclusion (53–55). Conversely, patients
administered chenodeoxycholic acid exhibited decreased
plasma VLDL triglyceride levels (56, 57). Familial hypertri-
glyceridemia, a disease characterized by elevated plasma
VLDL triglyceride levels, is associated with hepatic bile acid
overproduction, impaired absorption of bile acids (58, 59), and
decreased ASBT expression (60). Finally, hypertriglyceridemia
is observed in subjects with rare inherited defects in bile acid
synthesis (61, 62), suggesting that a decreased hepatic concen-
tration or flux of bile acids is the critical factor rather than
increased bile acid synthesis rates. In contrast to these human
studies, hepatic and plasma triglyceride levels were unchanged
in the Slc10a2 null mice. This finding is in agreement with
previous mouse studies that reported cholestyramine feeding
had no effect (63) or only weakly raised plasma triglyceride
levels in wild type mice (64). Although the mechanism respon-
sible for this species difference is not clear, hypertriglyceri-
demia is induced in gene-targeted mice with a defect in bile
acid biosynthesis (Cyp27/ mice, 63) or in the ability of the
hepatocyte to respond to bile acids (Fxr/ mice, 50). Taken
together, these results indicate that simply disrupting the re-
turn of bile acids to the liver in the enterohepatic circulation
(Slc10a2/ mice) is not sufficient to induce hypertriglyceri-
demia, and a second metabolic perturbation is required.
In conclusion, the results of these studies indicate that
Slc10a2 is the major mechanism for intestinal reclamation of
bile acids and crucial for maintenance of the bile acid pool. The
Slc10a2 null mice generated here provide a useful animal
model to identify the physiological mechanisms engaged to
maintain lipid homeostasis under conditions of chronic bile
acid malabsorption.
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